The 1,3,4-oxadiazole ring is a five-membered heterocycle comprising one oxygen and two nitrogen atoms, widely investigated in medicinal chemistry for its aromatic stability and bioisosterism with the carbonyl group in amides and esters. Heterocyclic scaffolds make up more than 85 percent of FDA-approved drug molecules, owing to their ability to form various intermolecular interactions including hydrogen bonding, metal coordination, π–π stacking, hydrophobic interactions, and van der Waals contacts. Several biological activities have been reported for 1,3,4-oxadiazoles, including antimicrobial, anti-inflammatory, antioxidant, and anticancer effects, with reported anticancer mechanisms including inhibition of growth factor receptors such as EGFR and VEGFR and induction of apoptosis in several tumor types. However, oxadiazole-based compounds had not previously been explored specifically for oligodendroglioma.

The synthesis proceeded through acid-catalyzed condensation of the appropriate hydrazides with aromatic aldehydes in absolute ethanol under reflux to afford hydrazone intermediates, which were then oxidatively cyclized using iodine and potassium carbonate in dimethyl sulfoxide at 100 °C for three to six hours to yield the final oxadiazole derivatives. Seven compounds were produced, designated A1 through A3 and B1 through B4, with the A series bearing a 5-chloro-2-nitrophenyl substituent and the B series bearing a 4-cyanophenyl substituent at the C-5 position of the oxadiazole ring. Characterization was carried out by FT-IR, proton NMR, carbon-13 NMR, and electron ionization mass spectrometry, with the infrared spectra supporting complete ring closure by the disappearance of the N–H stretching band and the amide carbonyl C=O stretching band of the hydrazones, alongside the appearance of characteristic C=N stretching of the oxadiazole ring and C–O–C asymmetric stretching.

Biological evaluation used the MTT colorimetric assay, which is based on the reduction of a yellow tetrazolium salt by mitochondrial dehydrogenase enzymes in metabolically active cells, producing an insoluble purple formazan product whose absorbance correlates directly with cell viability. Cells were plated at 10,000 cells per well in 96-well microplates, incubated for 24 hours, and exposed to serial concentrations of the test compounds ranging from 10 to 1,000 µg/mL, with cisplatin run in parallel as a reference drug. The IC50 values of all seven compounds were lower than that of cisplatin, which recorded an IC50 of 212.27 µg/mL against HS683 cells. Compounds bearing the 4-cyanophenyl group at C-5 were consistently more active than their A analogs, with IC50 values approximately half those of the matched pairs.

The selectivity index, calculated as the ratio of the IC50 against normal human astrocytes to the IC50 against HS683 cells, showed a clear advantage of the synthesized compounds over cisplatin, whose SI of 1.25 indicates near-equal toxicity toward tumor and normal cells. All seven compounds gave SI values greater than 1, with B2 achieving the highest SI of 14.55, followed by A2 with an SI exceeding 12.15, whose IC50 against normal human astrocytes exceeded 1,000 µg/mL, indicating minimal toxicity toward healthy brain cells. This favorable selectivity profile is particularly significant given that treatment-related adverse effects remain difficult to manage with current oligodendroglioma therapies, which typically involve radiotherapy and chemotherapy with temozolomide or the PCV regimen in conjunction with surgical resection.

Structure–activity relationship analysis revealed that the thiophen-2-yl group at the C-2 position produced the lowest IC50 values in both series, lower than those of their phenyl-substituted counterparts. Within compounds B, the activity order was B2 with the thienyl substituent, followed by B1 with pyridin-4-yl, B4 with 4-methylphenyl, and B3 with 4-fluorophenyl. Notably, pyridin-4-yl was the least active substituent among compounds A but the second-most active among compounds B, indicating that its contribution to activity depends on the electronic and steric character of the C-5 substituent. The thienyl compounds also possessed the highest selectivity indices in both series, suggesting that the thiophen-2-yl group was beneficial not only for cytotoxic potency but also for selectivity toward HS683 cells over normal astrocytes.

Molecular docking studies were performed against three kinase targets selected for their relevance to glioma pathogenesis: phosphatidylinositol 3-kinase alpha, cyclin-dependent kinase 2, and focal adhesion kinase. PI3Kα was included because of its role in the PI3K/AKT/mTOR pathway, CDK2 was included because of its overexpression in low-grade glioma subtypes, and FAK was selected based on its overexpression in glioma. The docking protocol was validated by re-docking the co-crystallized ligands, with root-mean-square deviation values all below 2.0 Å, confirming that the computational approach reliably reproduced experimental binding modes. Against PI3Kα, compounds B1 and B2 formed the strongest predicted interactions in the study, both forming hydrogen-acceptor contacts with LYS890 at distances of approximately 2.95 Å, with per-contact interaction energies of −9.0 and −8.8 kcal/mol respectively, involving the nitrile nitrogen of the 4-cyanophenyl group.

Against CDK2, compounds A produced scores of −6.654 to −7.087 kcal/mol, while compounds B ranged from −5.914 to −6.101 kcal/mol. B1 formed the richest interaction network among compounds B, with six contacts including two hydrogen-donor/acceptor interactions with LEU83 and PHE82, two hydrogen-acceptor contacts with LYS129 and ASN132, and a π–H contact with ILE10. B2 achieved a hydrogen-donor interaction between its sulfur atom and ASP145, suggesting that the sulfur atom of the thiophen-2-yl group is directly involved in the interaction. Against FAK, A2 achieved the strongest score among the synthesized compounds, and in both A2 and B2 the oxadiazole ring nitrogens served as the primary interaction atoms, forming two hydrogen-acceptor contacts with CYS502. This sulfur-specific contact with ASP145 was not observed for the phenyl- or heteroaryl-substituted analogs, providing a computational rationale for the superior activity of the thienyl compounds.

All seven compounds satisfied Lipinski’s rule of five, with molecular weights ranging from 248.24 to 319.68 g/mol and cLogP values ranging from 2.13 to 3.25, indicating moderate lipophilicity suitable for membrane permeation. The synthesized compounds had no hydrogen-bond donors and four to six hydrogen-bond acceptors, all below the maximum recommended limit. Topological polar surface area values ranged from 62.71 to 112.98 Ų, with compounds A showing higher values than compounds B. All final compounds were predicted to have high gastrointestinal absorption, and none were predicted to act as P-glycoprotein substrates, which may indicate a lower likelihood of efflux-mediated resistance. Notably, B1, B3, and B4 were predicted to permeate the blood–brain barrier, a relevant physicochemical feature for compounds intended to target glioma, although these predictions reflect theoretical permeability rather than confirmed central nervous system distribution and would require experimental validation.

The authors acknowledge that the proposed kinase targets are based on molecular docking and require experimental confirmation, and that further evaluation across additional glioma cell lines and in vivo models would help establish the broader therapeutic relevance of B2. Within the context of prior research, thioacetamide-based 1,3,4-oxadiazole derivatives have shown activity against C6 rat glioma cells, while ferulic acid- and caffeic acid-based oxadiazole hybrid derivatives have demonstrated activity against human glioblastoma cell lines U87, T98G, and LN229. Oxadiazole-based Akt/FAK inhibitors have also shown cytotoxic effects against C6 cells, supporting the relevance of FAK as a target within this chemical class. B2 extends this body of evidence to a previously unexamined glioma cell line and substituent pattern, reinforcing its potential as a lead candidate for future anti-glioma development.

Subject of Research: 1,3,4-Oxadiazole derivatives as potential anti-glioma agents: synthesis, characterization, in vitro cytotoxic activity against HS683 cells, and molecular docking

Article Title: 1,3,4-Oxadiazole derivatives as potential anti-glioma agents: synthesis, characterization, in vitro cytotoxic activity against HS683 cells, and molecular docking

Article References: Hashim, R. J., Alsaad, H. N., & Salman, H. H. (2026). 1,3,4-Oxadiazole derivatives as potential anti-glioma agents: synthesis, characterization, in vitro cytotoxic activity against HS683 cells, and molecular docking. Pharmacia, 73, Article e198079. https://doi.org/10.3897/pharmacia.73.e198079

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e198079

Keywords: 1,3,4-oxadiazole, anti-glioma agents, HS683, oligodendroglioma, molecular docking, MTT assay, selectivity index, drug-likeness, medicinal chemistry, kinase inhibitors, Oxadiazole, derivatives

The research, published in Nature, was led by scientists from The Jackson Laboratory, Yale University, and collaborators spanning ten countries. Drawing on data from the international Glioma Longitudinal Analysis Consortium, known as GLASS, the team analyzed tumors from 183 patients whose cancers were sampled both before treatment and again after recurrence. The samples were collected through more than 500 surgeries performed across North America, Europe, Asia, Australia and South America, allowing researchers to directly compare how the same tumors changed over time within individual patients.

The scale of the effort matters because IDH-mutant gliomas are rare. Individual institutions rarely accumulate enough paired samples to draw statistically meaningful conclusions about how these tumors evolve. “IDH-mutant gliomas are rare, which makes them challenging to study. Through this international collaboration, we were able to gather enough samples to characterize the most common ways each type of IDH-mutant glioma changes when it recurs,” said study author Frederick Varn, a JAX assistant professor who co-led the research. By pooling tumors from dozens of centers, the consortium could identify recurring patterns of evolution rather than isolated case anecdotes.

IDH-mutant gliomas primarily strike patients in their 30s and 40s, an age group in which a brain cancer diagnosis is particularly devastating. Although many patients live for years after diagnosis, these tumors almost always return, and when they do, they tend to stop responding to the treatments that initially held them in check. Understanding the genetic events that accompany that transition has been a central goal of the neuro-oncology field, because it may reveal vulnerabilities that could be targeted before resistance becomes entrenched.

The most striking findings emerged from comparing the two main subtypes of IDH-mutant glioma: oligodendroglioma and astrocytoma. Although both are defined by the same IDH mutation, the study showed that they follow sharply divergent evolutionary paths after treatment. Oligodendrogliomas tended to acquire new point mutations in genes that help drive tumor growth, adding fresh genetic damage one alteration at a time. Astrocytomas, by contrast, were far more likely to undergo large-scale chromosomal events, gaining and losing entire stretches of DNA as the disease progressed.

“Oligodendroglioma and astrocytoma are distinct tumor types, despite sharing the IDH mutation. This study shows that differences that exist when the tumor is first detected can set the stage for what happens after they are treated,” Varn said. In other words, the biology a tumor carries at diagnosis appears to shape the menu of evolutionary strategies available to it later. A tumor’s starting genome, in this view, is not merely a snapshot of its present state but a forecast of how it will respond to the selective pressures of therapy.

The treatment itself also left measurable marks. The chemotherapy drug temozolomide, a standard therapy for these tumors, appeared to leave distinct genetic fingerprints in recurrent tumors, a signature pattern of mutations that researchers could detect in the post-treatment samples. This observation underscores a growing theme in cancer genomics: therapy is not a neutral event but an evolutionary force, and the drugs used to control a tumor can actively shape the genetic changes it acquires as it fights back.

Crucially, some of the genetic changes observed at recurrence were associated with worse outcomes for patients. In astrocytomas, large-scale chromosomal abnormalities, including the duplication of entire sets of chromosomes and catastrophic events in which chromosomes broke apart and reassembled, were linked to shorter survival after recurrence. In oligodendrogliomas, new genetic changes that emerged as tumors returned, including alterations linked to uncontrolled cell growth, were likewise associated with poorer prognosis. These associations suggest that the mode of evolution is not just biologically interesting but clinically meaningful, potentially helping physicians identify which patients face the greatest risk once their disease returns.

The findings arrive at a moment of real momentum for the field. In 2024, the FDA approved vorasidenib, an IDH inhibitor, for certain patients with these tumors, marking a major therapeutic advance. While the new study focused specifically on the changes tumors undergo after radiation and chemotherapy rather than after IDH inhibition, its results can be applied to tailor treatment approaches to specific glioma types and to the genetic changes each type is likely to acquire as it evolves. A clinician who knows that an astrocytoma is prone to wholesale chromosomal upheaval, for example, may monitor and treat it differently than one facing an oligodendroglioma that accumulates targeted mutations.

“Our results and datasets provide a reference that helps understand how current and new therapies alter tumor behavior. Ultimately, we hope this will enable us to not just observe but to direct tumor behavior and make therapies more effective that way,” said Roel Verhaak, Ph.D., vice chair for research and professor of neurosurgery at Yale School of Medicine. That ambition, steering tumor evolution rather than merely documenting it, represents a shift in how researchers think about treating cancers that recur. The study was conducted through the GLASS Consortium with researchers from institutions across North America, Europe, Asia and Australia, and was funded by the National Institutes of Health along with additional public, philanthropic and institutional sources. For patients facing a disease that almost always returns, the work offers something concrete: a genetic map of what recurrence actually looks like, and a foundation for anticipating it.

Subject of Research: Genomic evolution of recurrent IDH-mutant gliomas

Article Title: What happens when brain tumors return? International study tracks genetic changes behind recurring cancers

Article References: What happens when brain tumors return? International study tracks genetic changes behind recurring cancers. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: glioma, IDH mutation, astrocytoma, oligodendroglioma, tumor recurrence, genomic evolution, temozolomide, GLASS Consortium, Jackson Laboratory, Yale University, Nature, treatment resistance

The answer, at least for a substantial share of patients, appears to be yes. Individuals who underwent gross total resection, meaning the surgeon removed all visible tumor, experienced a median progression-free survival of 76 months, compared with just 44 months for those who received only a biopsy. More striking still, when the investigators adjusted their analysis for age, tumor grade, and the use of adjuvant therapy, gross total resection stood out as an independent predictor of prolonged progression-free survival, while subtotal resection did not. In other words, in this cohort, the benefit was concentrated in the patients whose tumors were removed completely, a finding that carries real weight for surgical decision-making.

The study’s scale and molecular rigor distinguish it from much of the earlier literature. Before 2016, oligodendroglioma was diagnosed largely on histology, and older datasets inevitably mixed together tumors with very different biology. The 2021 World Health Organization classification resolved this ambiguity by requiring both IDH mutation and 1p/19q co-deletion for the diagnosis, creating a molecularly homogeneous group of tumors known to be unusually sensitive to chemotherapy and radiotherapy. Because prior studies of resection extent often included mixed glioma populations, some researchers had questioned whether maximal surgery truly mattered in oligodendroglioma, or whether the tumors’ chemosensitivity would render the scalpel’s reach irrelevant. This new cohort, drawn entirely from patients with molecularly confirmed disease, directly addresses that uncertainty.

The clinical portrait that emerges from the data is characteristic of the disease. Most patients, 173 of 267 with recorded presentation, came to medical attention because of seizures, a classic first sign of these tumors. The majority of lesions, 128 of 213, showed no contrast enhancement on imaging, reflecting the tumors’ typically indolent behavior, and nearly two-thirds, 170 of 267, arose in the frontal lobe, a location that influences both surgical accessibility and the risk of functional injury. Two hundred seven patients had grade 2 tumors and 70 had grade 3 disease, allowing the investigators to examine whether the value of resection differed across the grade spectrum.

Surgical practice in the cohort was diverse. Among 249 patients with a documented operation, subtotal resection was the most common procedure, performed in 115 cases, or 46.2 percent, followed by gross total resection in 97 cases, or 39.0 percent, and biopsy in 37 cases, or 14.9 percent. Awake craniotomy, in which the patient is roused during surgery so surgeons can map language and motor function in real time, was used in 25 of 173 applicable cases, or 14.5 percent. This technique, long championed for tumors in eloquent brain regions, allows more aggressive removal while safeguarding speech and movement, and its use in this cohort reflects the growing adoption of functional mapping in glioma surgery.

Safety outcomes were a central concern, because any argument for maximal resection collapses if it comes at the cost of neurological harm. Across the cohort, new permanent neurological deficits occurred in 24 of 254 patients, or 9.4 percent. Critically, the analysis found no observed increase in postoperative deficits among patients who underwent gross total resection compared with those who had less extensive surgery. That combination, a survival-linked procedure that does not appear to add measurable neurological risk in experienced hands, is precisely the profile that surgeons hope for when counseling patients about the aggressiveness of a first operation, which is often the single most consequential treatment decision in the disease’s long natural history.

The subgroup analyses added an important nuance. The progression-free survival advantage of gross total resection over biopsy held up among patients with grade 2 tumors, with a p-value of 0.032, but did not reach statistical significance in the smaller grade 3 subgroup, where the p-value was 0.549. The authors and commentators alike caution against over-reading the grade 3 result, which may reflect limited statistical power in a group of only 70 patients rather than a genuine absence of benefit. Still, the finding underscores that the strongest evidence for maximal safe resection currently lies in the lower-grade tumors, which are often diagnosed in young adults facing decades of life with their disease.

Median follow-up in the study was 57 months, with an interquartile range of 20 to 107 months, a window long enough to capture meaningful differences in progression but one that leaves open questions about overall survival, which the abstract does not report as a primary endpoint in this analysis. Progression-free survival matters enormously in oligodendroglioma because every progression typically triggers further surgery, radiation, or chemotherapy, and each intervention carries cumulative cognitive and neurological costs. Delaying the first progression can therefore translate into years of preserved quality of life, particularly in a disease where patients are often working, parenting, and planning careers at the time of diagnosis.

The study arrives amid a rapidly evolving treatment landscape. Molecular classification has already reshaped glioma care, and targeted drugs such as vorasidenib, which inhibits the mutant IDH enzyme, have shown promise in low-grade gliomas, raising the possibility that systemic therapy may one day reduce reliance on surgery. Yet the Johns Hopkins findings suggest that, for now, the extent of the first resection remains a powerful and modifiable prognostic factor. The results also align with a growing body of international work, including recent RANO resect group analyses, that has sought to define resection thresholds and prognostic classifications for IDH-mutant gliomas, moving the field toward standardized, evidence-based surgical goals.

For patients and clinicians, the practical message is one of careful, individualized planning. The data support pursuing gross total resection when it can be achieved safely, particularly in grade 2 tumors, while confirming that subtotal resection, though common, did not independently outperform biopsy in this cohort once other factors were accounted for. The authors emphasize that their study is retrospective and subject to the inherent limitations of such designs, including selection bias in which patients received which operation. Even so, in a disease where molecular definition has finally allowed clean comparisons, the study offers some of the strongest evidence to date that in oligodendroglioma, what the surgeon removes on day one still matters, and it matters without, in this experience, exacting a price in neurological function.

Subject of Research: Extent of surgical resection and postoperative outcomes in molecularly defined oligodendroglioma

Article Title: Surgical characteristics and postoperative outcomes in a retrospective cohort study of patients with molecularly defined oligodendroglioma

Article References: Kalluri, A. L., Carmichael, A., Rakovec, M., Jiang, K., Parker, M., Weber-Levine, C., Raj, D., Materi, J., Schreck, K. C., Aldecoa, I., Redmond, K. J., Holdhoff, M., Weingart, J., Brem, H., Ye, X., Bettegowda, C., Sánchez, J. J. G., & Rincon-Torroella, J. (2026). Surgical characteristics and postoperative outcomes in a retrospective cohort study of patients with molecularly defined oligodendroglioma. Journal of Neuro-Oncology, 180(1), Article 4. https://doi.org/10.1007/s11060-026-05800-3

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05800-3

Keywords: oligodendroglioma, IDH mutation, 1p/19q co-deletion, extent of resection, gross total resection, progression-free survival, neurosurgery, brain tumor, awake craniotomy, WHO classification, glioma, retrospective cohort study